Abstract
An anti-p185HER2/anti-CD3 humanized bispecific diabody was previously constructed from two cross-over single-chain Fv in which YH and VL domains of the parent antibodies are present on different polypeptides. Here this diabody is used to evaluate domain interface engineering strategies for enhancing the formation of functional heterodimers over inactive homodimers. A disulfide-stabilized diabody was obtained by introducing two cysteine mutations, VL L46C and VH D101C, at the anti-p185HER2.VL/VH interface. The fraction of recovered diabody that was functional following expression in Escherichia coli was improved for the disulfide-stabilized compared to the parent diabody (> 96% versus 72%), whereas the overall yield was > 60-fold lower. Eleven "knob-into-hole" diabodies were designed by molecular modeling of sterically complementary mutations at the two VL/VH interfaces. Replacements at either interface are sufficient to improve the fraction of functional heterodimer, while maintaining overall recoverable yields and affinity for both antigens close to that of the parent diabody. For example, diabody variant v5 containing the mutations VL Y87A:F98M and VH V37F:L45W at the anti-p185HER2 VL/VH interface was recovered as 92% functional heterodimer while maintaining overall recovered yield within twofold of the parent diabody. The binding affinity of v5 for p185HER2 extracellular domain and T cells is eightfold weaker and twofold stronger than for the parent diabody, respectively. Domain interface remodeling based upon either sterically complementary mutations or interchain disulfide bonds can facilitate the production of a functional diabody heterodimer. This study expands the scope of domain interface engineering by demonstrating the enhanced assembly of proteins interacting via two domain interfaces.
Full Text
The Full Text of this article is available as a PDF (5.5 MB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brinkmann U., Reiter Y., Jung S. H., Lee B., Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7538–7542. doi: 10.1073/pnas.90.16.7538. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Carter P., Bedouelle H., Winter G. Construction of heterodimer tyrosyl-tRNA synthetase shows tRNATyr interacts with both subunits. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1189–1192. doi: 10.1073/pnas.83.5.1189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Carter P., Kelley R. F., Rodrigues M. L., Snedecor B., Covarrubias M., Velligan M. D., Wong W. L., Rowland A. M., Kotts C. E., Carver M. E. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology (N Y) 1992 Feb;10(2):163–167. doi: 10.1038/nbt0292-163. [DOI] [PubMed] [Google Scholar]
- Carter P., Ridgway J., Zhu Z. Toward the production of bispecific antibody fragments for clinical applications. J Hematother. 1995 Oct;4(5):463–470. doi: 10.1089/scd.1.1995.4.463. [DOI] [PubMed] [Google Scholar]
- Eigenbrot C., Randal M., Presta L., Carter P., Kossiakoff A. A. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J Mol Biol. 1993 Feb 20;229(4):969–995. doi: 10.1006/jmbi.1993.1099. [DOI] [PubMed] [Google Scholar]
- Fendly B. M., Kotts C., Vetterlein D., Lewis G. D., Winget M., Carver M. E., Watson S. R., Sarup J., Saks S., Ullrich A. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Response Mod. 1990 Oct;9(5):449–455. [PubMed] [Google Scholar]
- Holliger P., Prospero T., Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6444–6448. doi: 10.1073/pnas.90.14.6444. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kelley R. F., O'Connell M. P. Thermodynamic analysis of an antibody functional epitope. Biochemistry. 1993 Jul 13;32(27):6828–6835. doi: 10.1021/bi00078a005. [DOI] [PubMed] [Google Scholar]
- O'Shea E. K., Lumb K. J., Kim P. S. Peptide 'Velcro': design of a heterodimeric coiled coil. Curr Biol. 1993 Oct 1;3(10):658–667. doi: 10.1016/0960-9822(93)90063-t. [DOI] [PubMed] [Google Scholar]
- Ponder J. W., Richards F. M. Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes. J Mol Biol. 1987 Feb 20;193(4):775–791. doi: 10.1016/0022-2836(87)90358-5. [DOI] [PubMed] [Google Scholar]
- Reiter Y., Brinkmann U., Webber K. O., Jung S. H., Lee B., Pastan I. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng. 1994 May;7(5):697–704. doi: 10.1093/protein/7.5.697. [DOI] [PubMed] [Google Scholar]
- Ridgway J. B., Presta L. G., Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996 Jul;9(7):617–621. doi: 10.1093/protein/9.7.617. [DOI] [PubMed] [Google Scholar]
- Robey E. A., Schachman H. K. Regeneration of active enzyme by formation of hybrids from inactive derivatives: implications for active sites shared between polypeptide chains of aspartate transcarbamoylase. Proc Natl Acad Sci U S A. 1985 Jan;82(2):361–365. doi: 10.1073/pnas.82.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zapata G., Ridgway J. B., Mordenti J., Osaka G., Wong W. L., Bennett G. L., Carter P. Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity. Protein Eng. 1995 Oct;8(10):1057–1062. doi: 10.1093/protein/8.10.1057. [DOI] [PubMed] [Google Scholar]
- Zhu Z., Carter P. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. J Immunol. 1995 Aug 15;155(4):1903–1910. [PubMed] [Google Scholar]